These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 2876445)

  • 21. Classification of neuroleptics: implications for tardive dyskinesia.
    Christensen AV
    Pol J Pharmacol Pharm; 1985; 37(3):295-309. PubMed ID: 2866499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological evaluation of SCH-12679: evidence for an in vivo antagonism of D1-dopamine receptors.
    Breese GR; Criswell HE; McQuade RD; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1990 Feb; 252(2):558-67. PubMed ID: 1968972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interaction between aminergic systems in mesolimbic structures: the importance of 5-HT2, D2 and D1 receptors in the olfactory tubercle for the atypical profile of neuroleptics.
    Cools AR; Prinssen E; Ellenbroek BA
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():618A-619A. PubMed ID: 1354068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dopamine D-1 and D-2 receptors in relation to reward and performance: a case for the D-1 receptor as a primary site of therapeutic action of neuroleptic drugs.
    Miller R; Wickens JR; Beninger RJ
    Prog Neurobiol; 1990; 34(2):143-83. PubMed ID: 1969668
    [No Abstract]   [Full Text] [Related]  

  • 25. Neuroleptic drugs and dopamine receptors.
    Strange PG
    Am J Psychiatry; 1991 Aug; 148(8):1101. PubMed ID: 1677238
    [No Abstract]   [Full Text] [Related]  

  • 26. A study of inhibition of cholera toxin-induced intestinal hypersecretion by neuroleptics.
    Larsen JJ
    Acta Pharmacol Toxicol (Copenh); 1982 Apr; 50(4):294-9. PubMed ID: 6125081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The dopamine D3 receptor as a key target for antipsychotics.
    Sokoloff P; Levesque D; Martres MP; Lannfelt L; Diaz G; Pilon C; Schwartz JC
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():456A-457A. PubMed ID: 1354048
    [No Abstract]   [Full Text] [Related]  

  • 28. Neuropharmacological studies on the neuroleptic potential of domperidone (R33812).
    Costall B; Fortune DH; Naylor RJ
    J Pharm Pharmacol; 1979 May; 31(5):344-7. PubMed ID: 37312
    [No Abstract]   [Full Text] [Related]  

  • 29. Bromerguride--an ergoline derivative with atypical neuroleptic properties.
    Löschmann PA; Horowski R; Wachtel H
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():263A-264A. PubMed ID: 1354031
    [No Abstract]   [Full Text] [Related]  

  • 30. [Neuroleptics or antipsychotic agents].
    Dresse A
    Rev Med Liege; 1996 Jan; 51(1):65-9. PubMed ID: 8701140
    [No Abstract]   [Full Text] [Related]  

  • 31. Differential development of therapeutic drugs for psychosis.
    Lewander T
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():654A-655A. PubMed ID: 1354072
    [No Abstract]   [Full Text] [Related]  

  • 32. Separation of dopamine D1 and D2 receptors.
    Dumbrille-Ross A; Niznik H; Seeman P
    Eur J Pharmacol; 1985 Mar; 110(1):151-2. PubMed ID: 3159588
    [No Abstract]   [Full Text] [Related]  

  • 33. 5-HT3 antagonists and ligands for dopamine D1- and autoreceptors offer new leads for antipsychotic drugs.
    Abbott A
    Trends Pharmacol Sci; 1990 Feb; 11(2):49-51. PubMed ID: 1969187
    [No Abstract]   [Full Text] [Related]  

  • 34. Limbic selective neuroleptics.
    Bischoff S
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():265A-266A. PubMed ID: 1354032
    [No Abstract]   [Full Text] [Related]  

  • 35. Neuroleptics and the ability of animals to experience pleasure.
    Thiebot MH; Guyon A; Assouly-Besse F; Biala G; Puech AJ
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():552A-553A. PubMed ID: 1354063
    [No Abstract]   [Full Text] [Related]  

  • 36. The effect of 2-substitution on conformations and brain concentrations of phenothiazine-neuroleptics in relation to dopamine-antagonism.
    Grol CJ; Rollema H; Asselbergs HW
    J Pharm Pharmacol; 1979 Oct; 31(10):667-71. PubMed ID: 41038
    [No Abstract]   [Full Text] [Related]  

  • 37. The effect of neuroleptics on cognition and diagnosis, and their influence on stereotypies.
    Campbell M
    J Ment Defic Res; 1987 Jun; 31 ( Pt 2)():220-5. PubMed ID: 2887661
    [No Abstract]   [Full Text] [Related]  

  • 38. Dopamine receptor diversity: molecular and pharmacological perspectives.
    Hartman DS; Civelli O
    Prog Drug Res; 1997; 48():173-94. PubMed ID: 9204687
    [No Abstract]   [Full Text] [Related]  

  • 39. Fencamfamine.
    DeLucia R; Planeta CS
    Gen Pharmacol; 1990; 21(2):161-3. PubMed ID: 1970543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drugs acting on brain dopamine receptors: a conceptual re-evaluation five years after the first selective D-1 antagonist.
    Waddington JL; O'Boyle KM
    Pharmacol Ther; 1989; 43(1):1-52. PubMed ID: 2675127
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.